CoChat

Resistance to vemurafenib resulting from a novel mutation in the BRAFV 600 E kinase domain

Open access
Wagenaar, Timothy R., Ma, Leyuan, Roscoe, Benjamin, Park, Sung Mi, Bolon, Daniel N., Green, Michael R. · 2014 · Pigment Cell & Melanoma Research
Cited by 59

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary: Resistance to the BRAF inhibitor vemurafenib poses a significant problem for the treatment of BRAFV 600 E‐positive melanomas. It is therefore critical to prospectively identify all vemurafenib resistance mechanisms prior to their emergence in the clinic. The vemurafenib resistance mechanisms described to date do not result from secondary mutations within BRAFV 600E. To search for possible mutations within BRAFV 600E that can confer drug resistance, we developed a systematic experimental approach involving targeted saturation mutagenesis, selection of drug‐resistant variants, and deep sequencing. We identified a single nucleotide substitution (T 1514 A, encoding L 505 H) that greatly increased drug resistance in cultured cells and mouse xenografts. The kinase activity of BRAFV 600 E/L 505 H was higher than that of BRAFV 600 E, resulting in cross‐resistance to a MEK inhibitor. However, BRAFV 600 E/L 505 H was less resistant to several other BRAF inhibitors whose binding sites were further from L 505 than that of PLX 4720. Our results identify a novel vemurafenib‐resistant mutant and provide insights into the treatment for melanomas bearing this mutation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pcmr.12171

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Wagenaar, T. R., Ma, L., Roscoe, B., Park, S. M., Bolon, D. N., & Green, M. R.
Venue
Pigment Cell & Melanoma Research
Publisher
Wiley
Published
2013-10-15
Volume
27
Issue
1
Pages
124-133
ISSN
  • 1755-1471 (ISSN-L)
  • 1755-148X
OpenAlex
W2096878348
Cited by
59
References
4
FWCI
2.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.